Alembic Pharmaceuticals Limited has informed the Exchange regarding 'Alembic Pharmaceuticals Limited receives Establishment Inspection Report (EIR) for its Injectable Facility (F-III) located at Karakhadi.'.
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Alembic Pharmaceuticals has received an Establishment Inspection Report (EIR) from the USFDA for its Injectable Facility (F-III) located at Karakhadi. The USFDA inspection was conducted from 9th to 18th February 2026, and the EIR was received on 13th May 2026. This confirms the facility has cleared its regulatory inspection successfully. The company had previously informed the exchange about this inspection in February 2026. Receiving a clean EIR is positive as it allows the facility to continue operating and exporting injectable products to the US market.
Positive for the company as it removes regulatory uncertainty around a key manufacturing facility. The injectable facility can now continue serving the US market without disruption, supporting revenue from exports.